Clinical trials: Invasive Aspergillosis
Invasive Pulmonary Aspergillosis
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)
The investigators aim to assess the safety and efficacy of nebulized liposomal amphotericin B (ALN) as a complementary therapy to the usual systemic treatment in patients with invasive pulmonary aspergillosis and the utility of a…
- Trial name
- NAIFI01 (NCT04267497)
- Testing
- Amphotericin B Liposomal 50 MG
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Aspergillosis
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive…
- Trial name
- NCT01207128
- Testing
- Voriconazole, micafungin
- Where
- 2 sites in United States
- Sponsor
- University of Arkansas
Pulmonary Invasive Aspergillosis
Application of an Electronic Nose in the Early Detection of ASpergillosis
The purpose of this study is to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls.
- Trial name
- AENEAS (NCT01395446)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Bronchoalveolar Lavage Fluid, Sensitivity and Specificity
Aspergillosis Detection Via EBC-GM in Ventilated Patients
Brief Research Proposal: Non-Invasive Detection of Invasive Pulmonary Aspergillosis in ICU Patients Background: Invasive Pulmonary Aspergillosis (IPA) is a critical threat to patients in ICUs, especially those undergoing…
- Conditions
- Bronchoalveolar Lavage Fluid, Sensitivity and Specificity, Critical Illness, Respiration Failure
- Trial name
- NCT06333379
- Testing
- Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lin Chen
Respiratory Infection, Invasive Pulmonary Aspergillosis
Early Diagnosis of Invasive Lung Aspergillosis
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in…
- Trial name
- NCT05860387
- Testing
- Next generation improvement of early invasive aspergillosis
- Where
- 7 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Nosocomial Infections, Bloodstream Infection
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.
- Conditions
- Nosocomial Infections, Bloodstream Infection, Invasive Aspergillosis
- Trial name
- Oncoped2006 (NCT00843804)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bonn
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Pulmonary Aspergillosis, Morality
Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.
Invasive tracheobronchial aspergillosis (ITBA) is an uncommon, but severe clinical form of Invasive Pulmonary Aspergillosis (IPA) in which the fungal infection is entirely or predominantly confined to the tracheobronchial tree.
- Trial name
- ITBA (NCT04077697)
- Testing
- RT-PCR for influenza
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Invasive Aspergillosis
Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study
Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy.
- Trial name
- ARPO (NCT06069505)
- Testing
- Aspergillus PCR
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Bart Rijnders
Aspergillosis, Influenza
Pharmacokinetics of Voriconazole in Adult ECMO Patients
Given the high burden of fungal co-infection in patients admitted to ICU and improved outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of anti-fungal are optimum to improve the dismal outcome…
- Conditions
- Aspergillosis, Influenza, Covid19
- Trial name
- NCT04868188
- Testing
- 5 blood samples, Determination of CYP2C19 genotype
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University Hospitals, Leicester
Ventilator Associated Pneumonia, Pulmonary Aspergillosis Invasive
Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia
Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the…
- Trial name
- ASPIC (NCT05671328)
- Testing
- Biological examinations performed on blood and BAL
- Where
- France
- Volunteers
- 263 people
- Sponsor
- University Hospital, Lille
Pulmonary Aspergillosis
Azole-resistance in Aspergillus
Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland
- Trial name
- NCT03443336
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Basel, Switzerland
Aspergillosis, Candidiasis
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
Fever and infection are serious complications of cancer treatment such as bone marrow transplant, especially when white blood cell counts are low.
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001937
- Testing
- FK463, Fluconazole
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Aspergillosis
Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe
Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate
- Trial name
- NCT02680808
- Testing
- Midazolam with F901318
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Invasive Pulmonary Aspergillosis, Invasive Fungal Disease
LFD of Aspergillus Antigen in Paediatrics
Many children and young people are at risk of invasive fungal disease (IFD), such as those who have had a haematopoietic stem cell transplants, those with an immune deficiency or those who are prescribed immunosuppressive drugs…
- Trial name
- LFD-AsPaeds (NCT05569824)
- Testing
- Lateral-flow Device
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St George's University Hospitals NHS Foundation Trust
Aspergillosis Invasive, Fungal Infection
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
The goal of this interventional single-arm study is to evaluate the interest of a multiparametric algorithm for individualization of first voriconazole maintenance doses for improvement of initial voriconazole exposure in adult…
- Conditions
- Aspergillosis Invasive, Fungal Infection, Hematologic Malignancy
- Trial name
- VORIPRECI (NCT06582186)
- Testing
- Individualization of first voriconazole maintenance doses
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Invasive Aspergillosis
Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in patients (pts) with hematologic malignancies.
- Trial name
- NCT01448226
- Where
- 22 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- Heidelberg University